<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="398">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05155969</url>
  </required_header>
  <id_info>
    <org_study_id>10110815</org_study_id>
    <nct_id>NCT05155969</nct_id>
  </id_info>
  <brief_title>Intravenous Esketamine on Prevention of Postoperative Depression in Patients Undergoing Cardiac Surgery</brief_title>
  <official_title>Evaluating the Effect of Subanaesthetic Dose of Esketamine on Prevention of Postoperative Depression in Patients Undergoing Cardiac Surgery：a Randomized, Double-blind, Placebo-controlled Pilot and Feasibility Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anshi Wu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Chao Yang Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Esketamine is a general anesthetic with anti-depressant effects at subanaesthetic doses. This&#xD;
      study hypothesized that intraoperative administration of ketamine would prevent or mitigate&#xD;
      postoperative depressive symptoms in surgical patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single subanaesthetic doses of i.v. esketamine may significantly improve symptoms in&#xD;
      psychiatric patients with major depression.&#xD;
&#xD;
      In patients undergoing cardiac surgery, postoperative depressive symptoms are common.&#xD;
&#xD;
      This study hypothesizes that low-dose esketamine has a preventive effect on postoperative&#xD;
      depression. However, evidence in this aspect is insufficient. The purpose of this study is to&#xD;
      investigate the effect of a subanaesthetic dose of ketamine on POD for patients undergoing&#xD;
      cardiac surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2021</start_date>
  <completion_date type="Anticipated">December 15, 2022</completion_date>
  <primary_completion_date type="Actual">December 5, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>Postoperative 5 Days</time_frame>
    <description>≥50% reduction in MADRS scores from the baseline value. The MADRS is a 10-item tool, with scores ranging from 0 to 60, and determining the severity of depression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anxiety symptom</measure>
    <time_frame>Postoperative 5 days</time_frame>
    <description>The anxious symptom is defined as a GAD-7 score no less than 10. The GAD-7 is a 7-item tool, with scores ranging from 0 to 21, The higher the score, the worse the anxiety.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative delirium</measure>
    <time_frame>1-7days after surgery, on the 30th day after surgery</time_frame>
    <description>Postoperative delirium will be assessed by the Confusion Assessment Method for the Intensive Care Unit Scale (CAM-ICU)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative insomnia</measure>
    <time_frame>Postoperative 5 days</time_frame>
    <description>Postoperative insomnia is defined as an ISI score of no less than 15. ISI is a 7-item tool, with scores ranging from 0 to 28, The higher the score, the worse insomnia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe pain</measure>
    <time_frame>Postoperative 3 days.</time_frame>
    <description>The incidence of severe pain within first postoperative three days, which is defined as mean and peak numerical rating scale (NRS) are higher than 5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative 30-day quality of life reported by SF-36</measure>
    <time_frame>postoperative 30 days</time_frame>
    <description>The quality of life will be evaluated by the 36-Item Short-Form Health Survey, SF-36 at postoperative 30 days SF-36 is a 36-item tool, with scores ranging from 1 to 100, The higher the score, the better the quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complications include psychiatric symptoms evaluated by Brief Psychiatric Rating Scale (BPRS)</measure>
    <time_frame>Postoperative 5 days</time_frame>
    <description>Postoperative complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychiatric manic symptoms assessed through the 11-item Young Mania Rating Scale (YMRS)</measure>
    <time_frame>Postoperative 5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychiatric dissociative symptoms measured by the Clinician-Administered Dissociative States Scale (CADSS).</measure>
    <time_frame>Postoperative 5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain</measure>
    <time_frame>Postoperative 2 days</time_frame>
    <description>The postoperative pain will be evaluated by Numerical pain scale（NRS） NRS is a tool with scores ranging from 1 to 10, the higher the score, the more intense the pain</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Postoperative Depression</condition>
  <arm_group>
    <arm_group_label>Eskatamine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low-dose esketamine (0.3 mg/kg in 100 ml normal saline) is intravenously infused in 40 minutes before anesthesia induction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (40 ml normal saline) is intravenously infused in 40 minutes before anesthesia induction.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esketamine</intervention_name>
    <description>esketamine (0.3 mg/kg in 100 ml normal saline) is intravenously infused 40 minutes before anesthesia induction</description>
    <arm_group_label>Eskatamine group</arm_group_label>
    <other_name>Ketamine hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Normal saline will be administrated intravenously at the dural opening, with a total dose of 0.5 ml/kg and continual infusion for 40 minutes.</description>
    <arm_group_label>Placebo group</arm_group_label>
    <other_name>saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1:Patients scheduled for heart surgery&#xD;
&#xD;
          -  2:Moderate to severe depressive symptom measured by the qualified psychiatric doctors&#xD;
&#xD;
          -  3:Over 18 years of age&#xD;
&#xD;
          -  4:American Society of Anesthesiologists physical status I-III&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1:History of epilepsy&#xD;
&#xD;
          -  2:Major depression disorder patients undergoing antidepressive therapy within 2 weeks&#xD;
&#xD;
          -  3: Psychiatric illness&#xD;
&#xD;
          -  4: Drug abuse&#xD;
&#xD;
          -  5:History of allergy to esketamine&#xD;
&#xD;
          -  6:Hyperthyroidism&#xD;
&#xD;
          -  7:Patients can not cooperate with investigators on psychiatric assessments&#xD;
&#xD;
          -  8:Pregnant or breastfeeding woman&#xD;
&#xD;
          -  9:refuse to sign informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anshi Wu Wu, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing Chao-Yang Hospital, Capital Medical Unive</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anshi Wu Wu, Ph.D</last_name>
    <phone>+861085351330</phone>
    <phone_ext>Wu</phone_ext>
    <email>wuanshi1965@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Chaoyang Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anshi Wu, MD</last_name>
      <phone>+8685231330</phone>
      <email>wuanshi1965@163.com</email>
    </contact>
    <investigator>
      <last_name>Anshi Wu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Chaoyang Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anshi Wu, Ph.D</last_name>
      <phone>+861085351330</phone>
      <phone_ext>Wu anshi</phone_ext>
      <email>wuanshi1965@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 8, 2021</study_first_submitted>
  <study_first_submitted_qc>December 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2021</study_first_posted>
  <last_update_submitted>December 13, 2021</last_update_submitted>
  <last_update_submitted_qc>December 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Chao Yang Hospital</investigator_affiliation>
    <investigator_full_name>Anshi Wu</investigator_full_name>
    <investigator_title>Head of Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>esketamine</keyword>
  <keyword>postoperative depression</keyword>
  <keyword>cardic surgey</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Esketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

